A Phase 1 interventional study of Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals and Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc. in Infection, sponsored by Sandoz. Completed. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-29.
Sponsored by Sandoz · Phase 1, Interventional, and Treatment
The purpose of this study is to demonstrate the bioequivalence of Azithromycin Monohydrate 600 mg Tablets.
Sandoz is the lead sponsor of 136 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Azithromycin Monohydrate 600mg Tablets
Drug: Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals
Zithromax (Azithromycin Dihydrate) 600mg Tablets
Drug: Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.
Bioequivalence based on AUC and Cmax
Time frame: 32 days
No study locations are listed for this record.
This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sandoz